Catalog5 refs
Dihexa
Nootropic & NeuroCognition, Mood & NeuroprotectionnootropicSynaptogenic Peptide | Cognitive EnhancementCognitiveResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Overview
Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic hexapeptide analog of angiotensin IV developed at Washington State University by Dr. Joseph Harding. It is approximately 10 million times more potent than brain-derived neurotrophic factor (BDNF) at promoting new synapse formation. Dihexa binds to and dimerizes the HGF receptor (c-Met), activating downstream signaling cascades involved in neuronal growth, survival, and connectivity. It is researched primarily as a cognitive enhancer and potential therapeutic approach for neurodegenerative conditions.
Primary Uses
Cognitive enhancement
Neurodegenerative diseases
Alzheimer's research
Memory enhancement
Promoting synaptogenesis
Neuronal survival support
Neurodegenerative conditions
Age-related memory loss
Cognitive decline
Learning Acceleration
Cognitive Recovery
Amyloid Reduction
Neuroinflammation Reduction
Synaptic Preservation
Dendritic Spine Formation
BDNF Upregulation
Angiogenesis Promotion
Memory improvement
Synaptogenesis
Alzheimer's disease (research)
Protocol Reference
Dose
5-20 mg oral or sublingual daily (range 5-40 mg, some report up to 80 mg)
Frequency
Once daily, effects can last up to 10 days
Half-life
8-12 days
Route
Oral · Sublingual · Intranasal
Evidence
Preclinical / Phase 2 / Early-stage research compound — no human clinical trials completed; doses extrapolated from animal studies / Emerging (disputed)
Research References· 2
Research Models
HumanMouseRatanimal modelsanimalsin vitro (cultured hippocampal neurons)
Also in Nootropic & Neuro